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There is a proliferation in the use of commercial herbal preparations, most notably liquid preparations of plant material packaged in plastic
containers. The quality of these herbal preparations has always and still remains questionable. A number of research institutes and research groups
in tertiary institutions throughout South Africa have embarked on the development of quality control programmes to test herbal medicines for
safety and efﬁcacy. However, very few of these groups have placed any emphasis on commercial herbal mixtures. This paper describes some
effects of toxic phthalates such as bis(2-ethylhexyl) phthalates, (a common plasticiser) used in cheap soft plastics and its metabolites. Analytical
methods for the determination, quantiﬁcation and monitoring of DEHP in herbal remedies to ensure safety are also highlighted.
© 2012 SAAB. Published by Elsevier B.V. All rights reserved.
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Despite its negative consequence on plant biodiversity and
destabilisation of most ecosystems, the inter-relationship between⁎ Corresponding author. Tel.: +27 33 2605130; fax: +27 33 2605897.
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doi:10.1016/j.sajb.2012.07.004society and nature, and the importance of herbal medicine to
human health, continues to dominate most medical traditions.
Plants form an integral part of virtually every medicinal
system in both modern and less civilised societies. South
Africa is one of the countries that are richly bestowed with
both floral and cultural diversity, and for this reason the
population exploits phytomedicines as part of their medicals reserved.
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either crude, unprocessed material, semi-processed or processed
as commercial herbal preparations (CHP) on various traditional
markets across the country (Mander, 1998; Ndhlala et al., 2011b;
Williams et al., 2000). As a result of urbanisation and the
consequent commercialisation of traditional health care, the
demand for herbal medicine has increased significantly in most
South African cities. There exists an insatiable market for these
products from most urban dwellers, on which traders capitalise.
Among the herbal products sold in urban areas, CHPs dominate
this market (Ndhlala et al., 2011b). This has become a modern
avenue for traditional plant-derived therapeutics in South Africa.
Although herbal medicines are widely used for the prevention,
diagnosis, treatment and management of disease, quality control
remains the biggest challenge. The widely held perception, by
herbal medicinal users, that natural plant-derived products are
safe, effective and non-toxic, has often left unsuspecting con-
sumers exposed to a multitude of risks associated with the use
and/or overuse of these products. It is important that the general
public be warned of the range of possible dangers that emanate
from using these plant-derived products. CHPs present some
complications to herbal medicine with regard to efficacy, safety
and quality. Chemical interactions between and among the
constituents of the component plant species in each preparation
could be diverse and result in synergism, antagonism, or toxicity
(Ncube et al., 2012; Ndhlala et al., 2009) within the human body.
Herbal preparations are produced and packaged by private
entrepreneurs (Ndhlala et al., 2009), and their quality, efficacy
and safety are determined by the manufacturing conditions,
condition and quality of material used for packaging, quantity
and type of component plant species used, as well as their storage
and handling, all of which remain solely under the control of the
manufacturer and distributor. Production and marketing of these
products have become a lucrative business in most cities of South
Africa, to such an extent that their quality and safety has often
been overlooked in an effort to make a profit. As a result,
consumers are offered products that are sub-standard and
packaged using cheap recycled plastic materials (Nair et al.,
2012). Could such herbal products deliver health benefits or are
they a potential health hazard to consumers? Logically, one
would be compelled to view such products as weapons of death.
Herbal preparations in general, are probably characterised with
impure, contaminated and sometimes lethally toxic components
that pose risks to humankind. A solution to this lies in intensive
screening of these products and the subsequent enacting of, and
strict adherence to, quality and safety regulations. Considering
the large number of people relying on these products on a day to
day basis and the associated health concerns, an interest was
aroused in their pharmacological and toxicological screening
(Nair et al., 2012; Ndhlala et al., 2010a,b, 2011a), in which both
positive and negative effects have been reported.
Among the negative reports on the CHP, the most recent and
potentially worrying discovery, is the isolation of a commercial
plasticiser di(2-ethylhexyl) phthalate (DEHP) from one of the
most popular preparations (Nair et al., 2012). This adds another
dimension to the safety and quality concerns of CHPs sold in
South African medicinal markets. An assessment of the possiblerisks of phthalate contaminants and its metabolites in herbal
products, as well as the minimum daily tolerable levels, are
outlined in this review. Analytical methods for the determination,
quantification and monitoring of DEHP in herbal remedies to
ensure safety are also highlighted.
2. Phthalate contaminants in herbal products
An increasing social concern has been aroused by the adverse
effects on public health caused by phthalates. Phthalates have
been shown to have endocrine disrupting properties resulting in
carcinogenic effects, metabolic disorders, and developmental and
reproductive defects (Hauser et al., 2006; Mahood et al., 2007;
Willhite, 2001). DEHP is used as a plasticiser in polyvinyl
chloride (PVC) plastics, rubber, cellulose and styrene production
to impart flexibility, strength, broad-range temperature tolerance,
and optical clarity (Chen et al., 2004). Phthalates are used in a
wide variety of consumer products and applications, that include
gelling agents, medical devices, cosmetics, adhesives, lubricants,
dispersants, food wrappings, nail polish, plastic goods, kitchen
plastic ware and emulsifying agents (Chen et al., 2004; Wormuth
et al., 2006). Since phthalates are not chemically bound to these
products, leaching and migration of these substances result in
significant environmental contamination and human exposure is
a common phenomenon (Clewell et al., 2008; Mahood et al.,
2007; Wormuth et al., 2006).
CHPs are, particularly those that are packed using cheap
recycled plastic materials, no exception to this contamination.
These contaminants could reach alarming levels in these products
in South Africa, owing to the fact that there are no effective
quality regulation mechanisms and/or policies with regard to the
manufacturing and handling of these products (Ndhlala et al.,
2011b). The highly toxic phthalate compound (DEHP) isolated
from one of the popular herbal preparations (‘Sejeso’ herbal
mixture) in South Africa, was found to be 43.3 mg/L (Nair et al.,
2012). An important concern about DEHP relates to its potential
to act as a non-genotoxic hepatocarcinogen, a reproductive and
developmentally toxic substance and its neurodegenerative
effects (Hauser et al., 2006; Koch et al., 2006; Willhite, 2001;
Wittassek and Angerer, 2008). Due to its widespread use in a
variety of consumer products and its associated health risks to
humans, the World Health Organisation (WHO) have im-
plemented strict guidelines with regard to the tolerable daily
intake levels of DEHP (WHO, 2003). The recommended dose for
patients using ‘Sejeso’ herbal mixture would translate to each
individual consuming on average 7.8 mg DEHP per day.
Compared to the daily tolerable levels of 8 μg/L and 1.5 mg/kg
for drinking water and food consumed respectively, this figure
(7.8 mg) is higher than the recommended values. These results
indicate how exposed consumers of these herbal products are. In
many cases, one patient might be using more than one CHP at
any given time per day, resulting in the accumulation of these
toxic contaminants to alarming levels. The risks could even be far
more, considering the fact that consumers rarely stick to the
recommended doses on the container labels, but tend to take
higher doses, with the belief that the healing effects will be faster
and more effective.
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confined to one herbal mixture but could be a common char-
acteristic of some plastic-packaged CHPs since most of them are
packaged in similar plastic containers. Phthalate contaminants in
herbal products could either be emanating from the plastic
containers in which they are packaged (to a larger extent) and/or
during the manufacturing process. The levels of these chemical
substances could have far reaching effects on the health of current
and future generations of the population relying on these herbal
products. Against a background of widespread use, ubiquitous
exposure and concerns about the ability of phthalates to cause
adverse health effects in humans, quality assurance of botanicals
and herbal preparations should be a prerequisite if these health
concerns are to be addressed. Very little research has been done
regarding the safety and quality of CHPs used in South Africa
and hence the need for further studies in this regard, particularly
on phthalates. The literature to this aspect (phthalates in CHPs
used in South Africa) is indeed scarce and hence this review is to
bring this to the fore to stimulate further research work on CHPs
and other food products.
3. DEHP biomarkers of exposure and effects
Through experimental and epidemiological studies, evidence
has accumulated for the association of other detrimental health
effects associated with phthalate exposure. Phthalates are rapidly
hydrolyzed followed by oxidation and are mainly excreted via
urine (Wittassek andAngerer, 2008). Thus, the content of phthalate
metabolites in human urine acts as an indicator of recent internal
exposure to the respective parent phthalate. Several studies have
assessed phthalate exposure of the general population by mea-
suring phthalate metabolites in human urine samples.
3.1. Phthalates and the reproductive development in human
infants
Exposure to environmental chemicals with antiandrogenic
activity, such as phthalates, is considered one of the causes for
the increased incidence of testicular dysgenesis syndrome
(TDS). The foetus is considered to be the most sensitive stage
of life to the potential developmental and reproductive toxicity
of phthalates (Wittassek et al., 2009). Some phthalates have
been found to be developmental and reproductive toxicants in
rats, with pronounced effect on the male reproductive system
(Borch et al., 2006; Foster, 2005; Gray et al., 2006). Recent
research has focused on the effects of certain phthalate esters on
reproduction, commonly on male reproductive development in
experimental animals. There are indications that phthalates may
be associated with abnormal sexual development and birth defects
in humans (McKee et al., 2004; Sharpe, 2008; Swan, 2008). The
pathways of androgen action are similar in both experimental
animals and humans, suggesting that phthalates may cause
comparable adverse effects on reproduction and development in
humans compared to experimental animals. Several epidemiolog-
ical studies suggest that environmental exposure to a number of
phthalates may be associated with adverse reproductive outcomes,
like alterations in semen parameters, DNA damage in sperm,reduced reproductive hormone levels in adult men and decreased
anogenital distance in male infants (Duty et al., 2003; Swan,
2008). The relationship between phthalate exposure and adverse
effects in human reproduction impacts negatively on their
offspring.
3.2. Phthalates and respiratory function, asthma, and allergy
The term allergy describes adverse health effects that might
result from the stimulation of a specific immune response
(Kimber and Dearman, 2010). One important aspect of allergic
sensitisation is that some chemicals may have qualitative, as well
as quantitative, effects on specific immune responses. The
possibility that phthalates may present a risk factor for the de-
velopment of allergies and asthma has been described in several
case studies (Bornehag et al., 2004; Bornehag and Nanberg, 2009;
Jaakkola et al., 2004; Kimber and Dearman, 2010). This has led to
the conclusion that some cleaning products used in domestic
environments are associated with an increased risk of asthma
(Bornehag et al., 2004; Rumchev et al., 2004). In addition,
occupational exposure to high concentrations of phthalate fumes
has been linked to asthma and other respiratory symptoms
(Andrasch et al., 1976; Markowitz, 1989; Nielsen et al., 1989). A
variety of respiratory symptoms such as cough, work-related
shortness of breath, wheezing and rhinitis, as well as a decline in
forced expiratory volume (FEV1) were found to be increased in
exposed workers compared to control groups (Kimber and
Dearman, 2010).
Persuasive as these investigations are to an association between
household cleaning and clinical diseases such as respiratory
reactions, they do not necessarily implicate cleaning materials as
being responsible for an increase in the incidence of allergic
sensitisation. The implication is that certain phthalates may act as
adjuvants and thereby predispose to, and/or otherwise enhance,
acquisition of allergic sensitisation (Kimber and Dearman, 2010).
It is appropriate, therefore, in advance of reviewing published data
on the association between phthalates and allergy, to consider the
nature of phthalates and their function as adjuvants. In this regard,
two independent studies were conducted in Sweden (Bornehag et
al., 2004) and Bulgaria (Kolarik et al., 2008) in which the
association between the phthalate content of house dust and
allergic symptoms in children was investigated. Both studies
reported a significant association between the concentration of
DEHP in house dust and allergic symptoms (asthma or wheezing)
in children. The implication that phthalates might play a role in the
development of respiratory disorders, asthma and allergy can
therefore not be overlooked.
4. The fate of DEHP: Its metabolites and their effects
Humans can be exposed to phthalates through ingestion,
inhalation and dermal contact when using phthalate-containing
consumer products (Silva et al., 2007). Human exposure to
phthalates is facilitated by nutrition, medical devices and personal
care products. After absorption, phthalates are readily metabolised
to hydrolytic monoesters which can be further metabolised to
other oxidative products before excretion in urine or faeces either
Table 1
The effect of three DEHP metabolites used as markers of human exposure.
Compound Toxic effects References
MEHP • Anti-androgenic (disruption of testosterone action) Grasso et al. (1993), Fan et al. (2010) and Piché et al. (2012)
• Inhibition of LH-stimulated steroid formation
MEOHP • May be toxic to the reproductive system Apostolidis et al. (2002), OSPAR (2002) and Bornehag et al. (2004)
• Confirmed animal carcinogen with unknown relevance
to humans
• Priority water pollutant
• Probable endocrine disruptor
• Prohibited in EU cosmetics
• Gastrointestinal or liver toxicity hazards
MEHHP • Immune system toxicity Apostolidis et al. (2002), OSPAR (2002), and Bornehag et al. (2004)
• Respiratory system toxicity
• Respiratory toxicity hazards
• Persistent, bioaccumulative toxicant
• Prohibited in EU cosmetics
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than 24 h (Herr et al., 2009). In the liver, phthalates are oxidised
by xenobiotic metabolising enzymes such as cytochrome P450
(Dirven et al., 1993). There are however, differences in the
excretion pattern of urinary DEHP metabolites between species.
Rats, for example, excrete more of the oxidised urinarymetabolites
than humans and monkeys which excrete (glucuronide) conjugat-
ed metabolites (Albro, 1986). The toxic effects of phthalate me-
tabolites are outlined in Table 1.
The main known DEHP metabolites excreted by humans
are mono (2-ethylhexyl) phthalate (MEHP), mono (5-carboxy-
2-ethylpentyl) phthalate, mono (2-ethyl-5-oxohexyl) phthalate
(MEOHP), and mono (2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP) (Dirven et al., 1993) represented in Fig. 1 and
Table 1. The other equally important phthalate metabolites
include phthalic acid (PA), monomethyl phthalate (MMP),
monoethyl phthalate (MEP), mono-3-carboxypropyl phthalate
(MCPP), mono-n-butyl phthalate (MBP), mono-isobutyl phthalate
(MiBP), monocyclohexyl phthalate (MCHP), monobenzyl phthal-
ate (MBzP), mono-n-octyl phthalate (MOP), mono-isononyl
phthalate (MNP), mono-isodecyl phthalate (MDP), mono-n-hexyl
phthalate (MHxP), mono-n-heptyl phthalate (MHpP), mono-2-
ethyl-5-carboxypentyl phthalate (MECPP), mono-carboxy-n-
heptyl phthalate (MCHpP), monocarboxy-isooctyl phthalate
(MCOP), mono-hydroxyisononyl phthalate (MHNP), mono-
oxoisononyl phthalate (MONP), and mono-carboxyisononyl
phthalate (MCNP) (Silva et al., 2007). These metabolites are
excreted in urine predominantly as glucuronide conjugates (Kato
et al., 2004). The differences in the rate of metabolism among
phthalates could result in urinary excretion of higher levels of the
monoester metabolites (MEHP, MEOHP and MEHHP) of the
phthalates with short alkyl chains than for DEHP, making these
metabolites suitable biomarkers for DEHP exposure (Kato et al.,
2004). The metabolism of DEHP involves the hydrolysis of one
ester bond, giving rise to MEHP, followed by oxidation to
MEOHP and MEHHP.5. Tolerable daily intake and minimal risk level
Based on the experimental data derived from animal studies,
the Scientific Committee on Toxicity, Ecotoxicity and the
Environment obtained tolerable daily intakes (TDI) and
minimal risk level (MRL) values for phthalates (Yen et al.,
2011). The WHO has set the TDI for DEHP at 8 μg/L for
drinking water and 1.5 mg/kg for food (WHO, 1996, 2003). It
is therefore important to carry out quality checks on the levels
of DEHP and its metabolites in commonly consumed products
like CHPs. As mentioned before, Nair et al. (2012) calculated
exposure levels of 7.8 mg DEHP per day in a commercial
herbal mixture (Sejeso herbal mixture, Ingwe brand). The
authors warned that the levels were alarming and reflected a
lack of effective quality control in the traditional medicine
sector in South Africa.
6. Analytical methods for determining DEHP
Several analytical methods have been reported for the
determination of DEHP in foods, biological fluids, and tissue
samples. These include high performance liquid chromatogra-
phy (HPLC), gas chromatography (GC), mass spectroscopy
(MS) and nuclear magnetic resonance techniques (NMR)
(Aignasse et al., 1995; Dirven et al., 1993; Faouzi et al.,
1999; Herr et al., 2009; Nair et al., 2012). These methods often
differ in extraction and sample preparation procedures
involved. Nevertheless, all the techniques are tedious and
time consuming (Aignasse et al., 1995). The idea is however, to
use a sensitive and specific analytical method to determine
DEHP and its metabolites in any matrix. HPLC has been the
most useful and sensitive method to determine concentrations
of DEHP and its metabolites in food and liquid matrices
(Kambia et al., 2001). However, as revealed by Torto et al.
(2007), Africa as a continent has its unique challenges for
analytical chemists in sample preparation for chromatographic
bis (2-ethylhexyl) phthalates (DEHP)
mono (2-ethylhexyl) phthalate (MEHP)
mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP)
mono (2-ethyl-5-oxohexyl) phthalate (MEOHP)
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Fig. 1. DEHP and its metabolites as biomarkers in human exposure.
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determination of phthalate esters and polycyclic aromatic hy-
drocarbons in both aquatic samples and sediments (Torto et al.,
2007).
In the investigation of simple methods for extraction of
phthalates, two approaches were employed either using liquid–
liquid extraction or solid-phase extraction. For liquid–liquid
extraction, extraction efficiencies for chloroform, dichloromethane
(DCM) and ethyl acetate were investigated for the determination of
phthalates in recovery experiments (Torto et al., 2007). The authors
concluded that DCM was the best extracting solvent for
phthalates as the other solvents formed emulsions, which were
difficult to separate from the aqueous medium and consequently
gave low recovery. Dichloromethane was cited as suitable
because of its low cost, availability in highly purified form,
inertness and easy separation from water because of its higher
density. Alumina was cited as the better suitable sorbent materialfor clean-up as compared to silica gel adsorbents (Fatoki and
Ogunfowokan, 1993).
Given the recent surge and popularity of plastic packaged
commercial herbal remedies, the South African government
should provide adequate support for analytical studies and
control of levels of DEHP in formulated products. WHO has
already published several technical guidelines for appropriate
approaches to assessing chemical toxins in herbal medicines
(WHO, 1996, 2003). Despite the fact that a lot of research has
been conducted on the effects of DEHP, its replacement with
safer chemicals still remains a challenge. Providing adequate
research facilities and experienced personnel, as well as setting
up common accepted analytical standards through bilateral
recognition and through international and regional regulatory
cooperation for herbal medicines should be considered.
7. Conclusions
In conclusion, DEHP is a liquid widely used to make plastics
more flexible. A potential exists for DEHP contamination of food
and CHPs during processing, handling, transportation and pack-
aging. Most cases of exposure occur from the leaching of DEHP
from plasticised products during their use. The level of exposures
is affected by the thickness of the plastic item, the tempera-
ture, storage conditions and the specific nature of the product.
Mandatory quality control mechanisms should therefore be
implemented for the manufacturing and packaging of products
in plastic containers intended for human consumption.
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